Effect of new nutraceutical formulation with policosanol, berberine, red yeast rice, cassia nomame, astaxantine and Q10 coenzyme in patients with low-moderate dyslipidemia associated with intolerance to statins and metabolic syndrome

Minerva Cardioangiol. 2018 Feb;66(1):124-125. doi: 10.23736/S0026-4725.17.04523-6.

Authors

Nicola Marchitto¹, Francesco Sindona², Alessandra Fabrizio³, Monica Mauti³, Simona Andreozzi⁴, Serenella Dalmaso⁵, Gianfranco Raimondi⁶

Affiliations

¹ Alfredo Fiorini Hospital, Terracina, Latina, Italy - n.marchitto@ausl.latina.it.
² Faculty of Internal Medicine, "Sapienza" University of Rome, Rome, Italy.
³ Department of Nursing Sciences, "Sapienza" University of Rome, Rome, Italy.
⁴ Faculty of Medicine and Surgery, "Sapienza" University of Rome, Rome, Italy.
⁵ Alfredo Fiorini Hospital, Terracina, Latina, Italy.
⁶ Department of Medico-Surgical Sciences and Biotechnologies, Faculty of Internal Medicine, "Sapienza" University of Rome, Rome, Italy.

PMID: 29264910
DOI: 10.23736/S0026-4725.17.04523-6

No abstract available

MeSH terms

Berberine / administration & dosage
Biological Products / administration & dosage
Cassia / chemistry
Dietary Supplements*
Dyslipidemias / therapy*
Fatty Alcohols / administration & dosage
Humans
Hydroxymethylglutaryl-CoA Reductase Inhibitors / administration & dosage
Hydroxymethylglutaryl-CoA Reductase Inhibitors / adverse effects
Metabolic Syndrome / therapy*
Treatment Outcome
Ubiquinone / administration & dosage
Ubiquinone / analogs & derivatives
Xanthophylls / administration & dosage

Substances

Biological Products
Fatty Alcohols
Hydroxymethylglutaryl-CoA Reductase Inhibitors
Xanthophylls
red yeast rice
Berberine
Ubiquinone
policosanol
astaxanthine
coenzyme Q10